Nano Dimension appointed Nadav Kidron to its Board of Directors. Kidron currently serves as the President and CEO of Oramed Pharmaceuticals, a significant shareholder in the company.
Kidron will chair the newly established Strategy and Capital Allocation Committee. This committee will evaluate strategic opportunities, potential shareholder capital returns, and the monetization of non-core assets.
The appointment supports an ongoing strategic review led by Chairman Phillip Borenstein. The company aims to strengthen its financial position and establish a disciplined framework for future growth.
Kidron cited Nano Dimension’s strong balance sheet and strategic flexibility as primary drivers for his involvement. He brings experience in public-company leadership and strategic transactions to the role.